Skip to main content

Table 2 Objective response rate by RECIST 1.1 assessment for 55 patients

From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Type of response

N (%)

Complete response

0

Partial response

14 (25%)

Stable disease

28 (51%)

Progressive disease

10 (18%)

Non-evaluable

3 (5%)

  1. RECIST Response Evaluation Criteria In Solid Tumors
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us